Royalty Pharma plc
NASDAQRoyalty Pharma heads into its Q1 2026 earnings call on May 8 with the stock at a one-year high — and its own CFO cashing out along the way. The most striking data point heading into the print is not in the options market or the borrow desk — it is the CFO's selling pattern. Terrance Coyne sold shares in four separate clusters between early March and late April, offloading roughly…
Snapshot as of 7 May 2026
Royalty Pharma heads into its Q1 2026 earnings call on May 8 with the stock at a one-year high — and its own CFO cashing out along the way. The most striking data point heading into the print is not in the options…
Royalty Pharma headed into its Q1 2026 print with options traders already positioned for upside — and the results gave them reason to hold that view. The earnings story is split down the middle. Adjusted EPS came in at…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RPRX — free to start on ORTEX.
Sign up for free →Open RPRX on ORTEX